Drug Repurposing for Viral Infectious Diseases: How Far Are We?

Trends Microbiol. 2018 Oct;26(10):865-876. doi: 10.1016/j.tim.2018.04.004. Epub 2018 May 11.

Abstract

Despite the recent advances in controlling some viral pathogens, most viral infections still lack specific treatment. Indeed, the need for effective therapeutic strategies to combat 'old', emergent, and re-emergent viruses is not paralleled by the approval of new antivirals. In the past years, drug repurposing combined with innovative approaches for drug validation, and with appropriate animal models, significantly contributed to the identification of new antiviral molecules and targets for therapeutic intervention. In this review, we describe the main strategies of drug repurposing in antiviral discovery, discuss the most promising candidates that could be repurposed to treat viral infections, and analyze the possible caveats of this trendy strategy of drug discovery.

Keywords: antiviral drugs; combination therapy; drug repurposing; emerging viruses; mechanism-based screening; phenotypic screening.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / therapeutic use*
  • CRISPR-Cas Systems
  • Drug Discovery*
  • Drug Repositioning*
  • Drug Therapy, Combination
  • Humans
  • Organoids
  • Orphan Drug Production
  • Virus Diseases / drug therapy*
  • Virus Diseases / genetics
  • Viruses / drug effects

Substances

  • Antiviral Agents